MedTrace Logo

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

NCT05422885 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-03-17

Study results available
· View outcomes & findings →

Summary

The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.

Conditions

  • Aging

Interventions

DRUG

Dasatinib

Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks

DRUG

Quercetin

Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks

Sponsors & Collaborators

  • Lewis Lipsitz

    lead OTHER

Principal Investigators

  • Lewis Lipsitz, MD · Hebrew Senior Life

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2024-01-24
Completion
2024-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422885 on ClinicalTrials.gov